Introduction
============

Subjective tinnitus is characterized by the perception of sound or noise in the absence of an objective physical sound source (Moller, [@B41]). There is convincing evidence from functional imaging (Crippa et al., [@B5]; Lanting et al., [@B33]) and neurophysiologic studies (Weisz et al., [@B65],[@B66]) that tinnitus is related to abnormal functioning of the central auditory system (Moller, [@B41]). Based on these findings repetitive transcranial magnetic stimulation (rTMS) of the temporal and temporoparietal cortex has been proposed as a potential treatment for chronic tinnitus (Eichhammer et al., [@B8]).

Transcranial magnetic stimulation (TMS) is a non-invasive tool for inducing electric currents in the brain (Hallett, [@B15]). Fast oscillating magnetic fields created by a strong electric current circulating within a coil, penetrate the skull and result in depolarization of superficial cortical neurons (Ridding and Rothwell, [@B47]). rTMS can induce alterations of neuronal activity that outlast the actual stimulation period for a considerable amount of time (Hallett, [@B15]). Therefore, this technique has gained increasing attention as a potential clinical tool for the treatment of different neuropsychiatric disorders. Although the direct effects of the magnetic field are limited to directly stimulated superficial brain areas (Siebner et al., [@B56]), indirect effects can also occur in functionally connected remote areas (Hallett, [@B15]; Siebner et al., [@B58]). Such remote stimulation effects have also been demonstrated in thalamic regions after temporal rTMS by using voxel-based morphometry (May et al., [@B39]).

Several clinical studies consistently showed a reduction of tinnitus severity after repeated 1 Hz rTMS applied to the temporal cortex, whereas sham treatment had no effect (Kleinjung et al., [@B24]; Plewnia et al., [@B45]; Rossi et al., [@B48]; Smith et al., [@B59]). However, treatment results are burdened by only moderate improvement and high inter-individual variability indicating the need for optimization strategies.

As hypothesized already more than 20 years ago (Jastreboff, [@B20]) and confirmed by recent neuroimaging findings, tinnitus is related to (i) abnormal activity in both auditory and non-auditory brain regions (Lanting et al., [@B34]; Leaver et al., [@B35]) and to (ii) abnormal functional connectivity between these regions (Schlee et al., [@B52], [@B50],[@B51]; De Ridder et al., [@B7]). In these studies the right dorsolateral prefrontal cortex has been identified as an important hub (Schlee et al., [@B52], [@B50],[@B51]; Vanneste et al., [@B62]). It has been hypothesized that this area might especially be related to the affective components of tinnitus (Vanneste et al., [@B62]; De Ridder et al., [@B7]; Langguth et al., [@B32]). It has even been speculated that based on the emotional relevance, involved limbic and paralimbic structures may effectively switch the perceived signal on and off (Rauschecker et al., [@B46]).

This is in line with electrophysiological studies that demonstrated the relevance of dysfunctional top-down inhibitory mechanisms originating in the prefrontal lobe for tinnitus generation (Norena et al., [@B43]). The critical relevance of the DLPFC for tinnitus annoyance has been affirmed by recent studies that demonstrated symptom reduction after bifrontal tDCS (Vanneste et al., [@B63]; Frank et al., [@B9]). Furthermore, it has been shown that rTMS over the DLPFC is apt to modulate the activity in functionally connected central limbic pathways such as the anterior cingulated cortex (Paus et al., [@B44]). Modulation of neuronal activity in the anterior cingulate, parahippocampus, and auditory cortex has also been reported in tinnitus patients after transcranial direct current stimulation of the prefrontal cortex (Vanneste and De Ridder, [@B60]).

A further rationale for low-frequency stimulation of the right DLPFC derives from affective research. Frontal asymmetry is known to influence emotion regulation and the emotional reaction to sensory stimuli (Davidson, [@B6]; Schmidt and Hanslmayr, [@B53]). It has also been shown that low-frequency rTMS of the right DLPFC exerts antidepressant effects of similar magnitude like high frequency rTMS of the left DLPC, which is conventionally applied in depressive disorders (Schutter, [@B54]).

Based on these data and the right lateralized alterations of frontal cortex activity in tinnitus patients (Schlee et al., [@B52]) we hypothesized that low-frequency rTMS of the right DLPFC might enhance treatment effects of low-frequency rTMS in tinnitus patients and compared the combined prefrontal and temporal rTMS therapy in tinnitus patients with the standard procedure of temporal rTMS.

Patients and Methods
====================

Fifty-six patients with chronic unilateral or bilateral tinnitus were enrolled in the study after having given written informed consent. The study has been registered with [clinicaltrials.gov](clinicaltrials.gov) (<http://clinicaltrials.gov/ct2/show/NCT01261949>), was approved by the local ethics committee and performed according to the declarations of Helsinki. All patients suffered from disturbing tinnitus and had tried several standard treatment modalities such as cognitive behavioral therapy, hearing aids, white-noise generators, vasodilators, or antidepressants in the past. Normal middle ear status was demonstrated by tympanometry, stapedius reflex tests, and otoscopy. Patients with a history of seizures, a suspected diagnosis of organic brain damage, as well as patients with cardiac pacemakers, mobile metal implants, or implanted medication pumps were excluded. Sample characteristics are provided in Table [1](#T1){ref-type="table"}. All data in the text and table is given as mean ± SD. rTMS was applied with the use of a Medtronic system with a figure-8 coil (Cool B-65 Butterfly; Medtronic, Minneapolis, MN, USA). Patients were enrolled in the study on a Monday and received stimulation on 10 subsequent working days. Patients were randomly assigned to one of two treatment protocols. One protocol (standard protocol) consisted of 2000 stimuli at a frequency of 1 Hz and an intensity of 110% resting motor threshold (RMT) over the left auditory cortex. In the second treatment protocol (combined protocol), low-frequency stimulation (1000 stimuli, 1 Hz, 110% motor threshold) applied to the right DLPFC preceded left temporal stimulation (1000 Stimuli, 1 Hz, 110% RMT). Thus, the total number of applied stimuli per session was identical for both groups. Stimulation was administered over the right DLPC and the left temporal cortex regardless of handedness or tinnitus laterality (Kleinjung et al., [@B26], [@B23]). The handle of the coil was pointing upward. Thus, the induced current in the brain was directed approximately perpendicular to the location of the superior temporal gyrus. During treatment the coil was held with a mechanical arm. In the combined stimulation group, the TMS coil was localized over the right DLPFC according to a standard algorithm by moving the coil from the optimal position for stimulation of the left abductor minimi 6 cm in the anterior direction and transferring this spot to the contralateral hemisphere in respect of the distance to the sagittal axis of the skull (George et al., [@B12]). The RMT was determined over the left motor cortex for the right abductor digiti minimi and defined as the lowest intensity at which at least four of eight consecutive MEPs were 50 mV in amplitude while the muscle being investigated was at rest. Tinnitus severity was assessed before treatment (baseline), at the end of treatment (week 2), and during a certain follow-up period after rTMS treatment (week 4 and week 12). Tinnitus assessments included the German versions of the tinnitus questionnaire (TQ; Goebel and Hiller, [@B14]), the Tinnitus Handicap Inventory (Kleinjung et al., [@B25]), the Beck Depression Inventory (Beck and Steer, [@B2]), several tinnitus numeric rating scales (loudness, discomfort, annoyance, distractibility, unpleasantness; Landgrebe et al., [@B30]), and a quality of life scale (WHOQOL-BREF; Murphy et al., [@B42]).

###### 

**Clinical and demographic characteristics (mean ± SD)**.

                                                          1 Hz          1/1 Hz          *T*/χ^2^   df   p
  ------------------------------------------------------- ------------- --------------- ---------- ---- -------
  Age                                                     46.5 ± 14.9   51.1 ± 13.9     1.196      54   0.237
  Preceding treatments                                    2.5 ± 0.95    2.9 ± 0.56      2.063      53   0.044
  Tinnitus duration (in months)                           81.8 ± 78.0   109.6 ± 129.9   0.968      52   0.337
  Gender (male/female)                                    23/7          19/7            0.096      1    0.757
  Tinnitus laterality (right/left/both)                   2/3/22        1/7/14          3,235      2    0.198
  THI total score at baseline                             41.5 ± 19.7   39.6 ± 22.4     −0.328     54   0.744
  BDI total score at baseline                             8.9 ± 7.7     6.9 ± 5.6       −1.103     54   0.275
  TQ total score at baseline                              39.5 ± 17.7   35.9 ± 17.1     −0.774     54   0.442
  Audiogram (average from 125 Hz to 8 kHz of both ears)   20.8 ± 14.0   25.5 ± 17.8     0.650      54   0.519

Statistical Analysis
====================

The data analysis was based on data of the Tinnitus Research Initiative Database. Data management was conducted according to the Data Handling Plan (TRI-DHP V07, May 9th, 2011). Data analysis was conducted according to the Standard Operating Procedure (TRI-SA V01, May 9th, 2011), thereby following a study-specific Statistical Analysis Plan (SAP-003, May 18th, 2011) that was written according to the SAP template (TRI-SAP V01, May 12th, 2011). All documents are to be found under <http://database.tinnitusresearch.org/>.

The statistical analysis was performed on an intention-to-treat basis including all patients who participated in at least one measurement time point using a last observation carried forward or backward approach. Primary outcome was the change in TQ scores from baseline to week 2. For this purpose, we conducted an analysis of variance (ANOVA) with the within-subjects factor time (baseline vs. week 2) and the between-subjects factor group (combined vs. temporal group). Secondary outcome measures and exploratory analyses included chi-square tests for the variables group and treatment response which was defined as amelioration of at least 5 points in the TQ. We pooled the group of responders and non-responders of both treatments and compared them in regard to demographic and clinical characteristics with chi-square and *t*-tests. Furthermore, we compared baseline corrected TQ scores (week 2 minus baseline) between the treatment groups with Student's *t*-tests. In addition, we again conducted an ANOVA with the factor group (between-subjects factor) and time (within-subjects factor), this time including five measurement time points (screening, baseline, week 2, week 4, and week 12). This ANOVA was also computed for all other secondary outcome parameters (i.e., THI, BDI, and WHOQoL-BREF). Furthermore, we compared baseline corrected TQ scores (week 2 minus baseline; week 4 minus baseline) between the treatment groups. The statistical threshold for alpha error was set at 0.05. The analysis of secondary outcome parameters followed an exploratory approach, without corrections for multiple comparisons.

Results
=======

Both stimulation protocols were well tolerated, and all patients except one completed the treatment. This patient (combined stimulation group) refused further stimulation after day 3 because she feared a possible deterioration of the symptoms. A total of seven patients (including the one mentioned before) did not complete the course of the study (not shown up for follow-up-visit without giving further explanation). Three of them were treated in the combined stimulation group, four in the conventional group. Transient mild to moderate headache and feelings of twitching muscles at the stimulation site were reported as side effects. Serious adverse or side effects were not observed.

Primary outcome analysis indicated a significant change over time for both groups as indicated by a significant main effect of time (*F* = 6.1; df = 1.54; *p* = 0.017), but no group differences (main effect of group: *F* = 0.8; df = 1.54; *p* = 0.375; interaction effect time by group *F* = 0.434; df = 1.54; *p* = 0.513).

Response rate was comparable between groups (combined: 40%; temporal: 37%; χ^2^ = 0.1; df = 1; *p* = 0.800). Effect sizes were near zero for the non-responder groups (combined: *d* = 0.085; temporal: *d* = 0.104) and medium to high for the responder groups (combined: *d* = 0.700; temporal: *d* = 0.454). Contrasts between these groups indicated no significant differences for age, gender, tinnitus laterality, duration, and hearing loss. We only found an effect for the change in TQ and THI from screening to baseline for the non-responder group in contrast to the responder group of the combined treatment (TQ: *T* = 2.156; df = 24; *p* = 0.041; THI: *T* = 3.675; df = 24; *p* = 0.001), i.e., there was a reduction of questionnaire scores from screening to baseline for the non-responder (TQ: −5.2 ± 11.7; THI: −5.6 ± 7.7) and an increase for the responder group (TQ: 3.5 ± 6.1; THI: 5.8 ± 8.0).

Comparable to the primary outcome analysis, ANOVAs with five time points for TQ, THI, and BDI indicated significant main effects of time (all *F*s \> 2.3; df = 4.212; all *p*s \< 0.065) and neither significant effects of group (all *F*s \< 2.6; df = 1.53; all *p*s \> 0.115) nor time by group (all *F*s \< 0.9; df = 4.216; all *p*s \> 0.462). *Post hoc* tests indicated an amelioration of symptoms after beginning of treatment and a return to baseline levels during the last follow-up (see Figure [1](#F1){ref-type="fig"}), i.e., tinnitus scores were significantly bettered for week 2 and week 4 in contrast to screening, baseline and follow-up.

![**(A)** Tinnitus Questionnaire Score (TQ; mean ± SEM), **(B)** Tinnitus Handicap Inventory (THI; mean ± SEM), and **(C)** Beck Depression Inventory (BDI; mean ± SEM).](fnsys-05-00088-g001){#F1}

Baseline corrected group contrasts (week 2 minus baseline; week 4 minus baseline) indicated no significant differences for week 2 (all *p*s \> 0.265) and week 4 (all *p*s \> 0.088) for TQ, THI, and BDI. Range of effect sizes were between 0.168 and 0.461 (0.176 for primary outcome analysis) indicating more pronounced improvement for the combined group in contrast to the temporal group for all variables.

Discussion
==========

The main finding of this trial is that additional low-frequency stimulation of the right DLPFC failed to significantly improve the effects of low-frequency temporal stimulation in the treatment of tinnitus. However, on a descriptive level the combined treatment protocol yielded better results in all assessment instruments that have been applied. Primary outcome analysis showed an effect size of 0.176 (group contrast in week 2) indicating a small effect according to Cohen ([@B4]). Thus, the effect size was smaller than expected resulting in limited power and the failure to demonstrate significant effects. In this context it should be noted that significant improvement after rTMS was observed in both stimulation groups. The effect size for responders from temporal stimulation was medium (*d* = 0.45) for the responders from the combined stimulation protocol high (*d* = 0.70) according to Cohen ([@B4]). Interestingly, the responder group differed significantly from non-responders in the change of THI and TQ scores from screening to baseline (non-responders: mean effect −4 TQ/7 THI points; responders: mean effect +2 TQ/THI points). This might be interpreted as a hint for the induction of homeostatic effects by TMS (Siebner et al., [@B57]). Further analysis did not reveal any differences between responders and non-responders in respect to gender, age, tinnitus duration, laterality, number of previous treatments, hearing loss, numeric rating scales, and values (screening/baseline) for THI, BDI, and TQ.

A further important finding was the decrease of mean baseline values for TQ, THI (for the 1/1-Hz group), and BDI from screening to baseline. This effect was similar in both stimulation groups and may have several reasons. First screening scores are based on completion of the TQ at home before the first consultation in our tinnitus clinic. The examination and consultation in the tinnitus clinic, which also involves counseling, may have resulted in the reduction of the tinnitus scores. Alternatively the improvement can be interpreted as an anticipation effect. Similar effects were observed in patients enrolled in waiting list control groups (Hesser et al., [@B19]).

Facing the fact that the combined stimulation group has been compared to an actively treated control group \[that has undergone an already established standard treatment protocol (Kleinjung et al., [@B24]; Plewnia et al., [@B45]; Rossi et al., [@B48]; Smith et al., [@B59])\] it would be a bit too early to draw the conclusion that the small effect sizes might not possibly reflect clinically relevant changes especially taking into consideration the much higher effect sizes of the responder group. Even if this pilot study might have been designed with limited power presumptions, the results suggest at least that the applied combined study protocol did prove to be non-inferior in comparison to the established stimulation pattern of 1 Hz to temporal targets.

In this study all patients received rTMS over the left temporal cortex and in the combined group additionally over the right DLPFC. For both targets it remains a matter of debate, whether a more individualized strategy may not be more efficient. For the temporal cortex there are conflicting results whether stimulation ipsi- or contra-lateral to the perceived tinnitus laterality is more efficient (Frank et al., [@B10]; Khedr et al., [@B21]). We chose left temporal stimulation in all patients for better comparison with previous studies that investigated enhancement strategies for rTMS (Kleinjung et al., [@B23], [@B28]; Langguth et al., [@B31]). With respect to frontal stimulation individualized targeting based on function imaging data revealed conflicting results as well (Kimbrell et al., [@B22]; Herwig et al., [@B18]) and more consistent antidepressant efficacy has been reported for low-frequency rTMS over the right DLPFC independent from imaging data (Schutter, [@B54]).

There is growing evidence from many recent neuroimaging studies that the influence of non-auditory brain structures may have been underestimated in the pathophysiology of chronic tinnitus in the past. A study investigating long-range connectivity of brain areas in patients suffering from chronic tinnitus by means of magnetoencephalography detected mainly the prefrontal cortex and the orbitofrontal region as hubs in tinnitus related networks (Schlee et al., [@B51]). Moreover with increasing tinnitus duration non-auditory areas seem to gain importance in tinnitus related networks in comparison to auditory areas (Schlee et al., [@B51]). But not only the DLPFC and neighboring regions seem to be of decisive relevance; also the left hippocampus (Landgrebe et al., [@B29]), parahippocampus (Lockwood et al., [@B37]; Schecklmann et al., [@B49]), the anterior (Plewnia et al., [@B45]) and posterior cingulate cortex (Vanneste et al., [@B62]; Schecklmann et al., [@B49]), the temporoparietal junction (=auditory association area; Shulman, [@B55]; Giraud et al., [@B13]; Lockwood et al., [@B36]; Gardner et al., [@B11]), the dorsolateral prefrontal cortex (Mirz et al., [@B40]; Voisin et al., [@B64]), and the cerebellum (Lanting et al., [@B34]) have consistently been shown to exert functional influence in chronic tinnitus.

Possibly other rTMS techniques with different target locations, frequencies, and stimulation protocols (e.g., burst protocols; Arfeller et al., [@B1]; Kleinjung and Langguth, [@B27]) might represent promising approaches. Very recently a new rTMS coil, the so-called double-cone-coil with increased stimulation depth in the brain, has been introduced. Based on the use of this device it has been shown that a direct modulating influence of rTMS can be exerted to the limbic system, namely the anterior cingulate cortex (Hayward et al., [@B16]). In first clinical trials this new technique has been proven to be safe and its application is feasible and well tolerated (personal communication S Vanneste and D de Ridder).

Even if the present study has not been placebo controlled, the results further support the efficacy of low-frequency rTMS for the treatment of tinnitus as demonstrated in previous studies (Kleinjung et al., [@B24]; Plewnia et al., [@B45]; Rossi et al., [@B48]; Smith et al., [@B59]). The inter-individual variability has been high in both treatment groups, highlighting the relevance of a more individualized treatment approach. The limited accuracy of the coil positioning procedure over the DLPFC together with the large anatomic inter-individual variability of the DLPFC in Brodman Area 9 and Brodman Area 46 (Herbsman et al., [@B17]) may play a role in this context as well as potential genetic influences on neuromodulatory effects as proposed for the BDNF polymorphisms (Cheeran et al., [@B3]). It has been shown that clinical characteristics have only limited value for predicting treatment outcome (Frank et al., [@B10]). Neuroimaging such as electro- or magnet-encephalography may be more promising for identifying patients who may respond well on specific stimulation protocols (Lorenz et al., [@B38]; Vanneste et al., [@B61]). This may lead to the development of individualized multi-site-rTMS-stimulation techniques for the treatment of tinnitus, but also in other indications such as depression or chronic pain.
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